Rovelizumab

N/A

Report date: 2022/02/21 14:18:58

Base Information

Drug NameRovelizumab
Drug Alias NameLeukArrestHu23F2G23F2G
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-L/beta-2 (LFA-1) antagonists
TargetsIntegrin alpha-L/beta-2 (LFA-1)
Therapy Area/IndicationsVascular restenosisShockMyocardial Infarction +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIcos Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIcos Corporation
Active IndicationsN/A
Inactive IndicationsVascular restenosisShockMyocardial Infarction +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia